These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Present-day treatment of dyskinesias (author's transl)].
    Author: Fonsegrive J.
    Journal: Sem Hop; ; 55(1-2):88-9. PubMed ID: 34220.
    Abstract:
    The physiopathological processes involved in the production of dyskinesias will become clearer as our knowledge of neuromediators and their receptors increases. Among centrally-acting molecules, pimozide and the substituted benzamides block dopaminergic receptors only. Tiapride, which is a substituted benzamide, has an original neurotropic action expressed as relaxant and antidyskinetic activity. It is perfectly well-tolerated and is simple to prescribe, which has made it a product for use in general practice where very encouraging results have been obtained, especially in the two cases reported: an elderly patient with buccofacial dyskinesia often seen in this age group, and a patient with severe dopa-induced dyskinesias.
    [Abstract] [Full Text] [Related] [New Search]